Literature DB >> 17141088

Primed fibroblasts and exogenous decorin: potential treatments for subacute vocal fold scar.

Priya Krishna1, Clark A Rosen, Ryan C Branski, Alan Wells, Patricia A Hebda.   

Abstract

OBJECTIVE: To investigate hepatocyte growth factor (HGF) primed fibroblasts and decorin application on skin and vocal fold fibroblasts in vitro and in vivo in rabbit vocal fold scar model. STUDY DESIGN AND
SETTING: Vocal fold and skin fibroblasts underwent five in vitro treatment conditions: control, epidermal growth factor, HGF, both decorin and HGF, and decorin alone. Hyaluronic acid and collagen enzyme-linked immunosorbent assays were performed. In vivo, 12 rabbits underwent unilateral vocal fold stripping. Injured vocal folds were then injected with skin fibroblasts, HGF, HGF-primed fibroblasts and decorin, or decorin. Outcomes included histologic and lamina propria height analyses.
RESULTS: In vitro, HGF increased hyaluronic acid synthesis in vocal fold fibroblasts (P<0.001). HGF and decorin treatment diminished collagen secretion (P<0.01). In vivo, histologic findings indicated minimal difference in collagen amount between treatment groups.
CONCLUSION: HGF and decorin together may decrease collagen production by skin and vocal fold fibroblasts. Fibroblast transplantation into scarred vocal folds has equivocal benefit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141088     DOI: 10.1016/j.otohns.2006.07.011

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  11 in total

1.  Biosimulation of inflammation and healing in surgically injured vocal folds.

Authors:  Nicole Y K Li; Yoram Vodovotz; Patricia A Hebda; Katherine Verdolini Abbott
Journal:  Ann Otol Rhinol Laryngol       Date:  2010-06       Impact factor: 1.547

2.  Methodology for the establishment of primary porcine vocal fold epithelial cell cultures.

Authors:  Elizabeth Erickson-DiRenzo; Ciara Leydon; Susan L Thibeault
Journal:  Laryngoscope       Date:  2019-03-08       Impact factor: 3.325

3.  The effects of decorin and HGF-primed vocal fold fibroblasts in vitro and ex vivo in a porcine model of vocal fold scarring.

Authors:  Priya Krishna; Michael Regner; Joel Palko; Fang Liu; Steve Abramowitch; Jack Jiang; Alan Wells
Journal:  Laryngoscope       Date:  2010-11       Impact factor: 3.325

4.  Prospective multi-arm evaluation of surgical treatments for vocal fold scar and pathologic sulcus vocalis.

Authors:  Nathan V Welham; Seong Hee Choi; Seth H Dailey; Charles N Ford; Jack J Jiang; Diane M Bless
Journal:  Laryngoscope       Date:  2011-05-06       Impact factor: 3.325

5.  Characterization of human vocal fold fibroblasts derived from chronic scar.

Authors:  Marie E Jetté; Supriya D Hayer; Susan L Thibeault
Journal:  Laryngoscope       Date:  2013-03       Impact factor: 3.325

6.  A rat excised larynx model of vocal fold scar.

Authors:  Nathan V Welham; Douglas W Montequin; Ichiro Tateya; Tomoko Tateya; Seong Hee Choi; Diane M Bless
Journal:  J Speech Lang Hear Res       Date:  2009-08       Impact factor: 2.297

7.  Intra-articular decorin influences the fibrosis genetic expression profile in a rabbit model of joint contracture.

Authors:  M P Abdel; M E Morrey; J D Barlow; D E Grill; C P Kolbert; K N An; S P Steinmann; B F Morrey; J Sanchez-Sotelo
Journal:  Bone Joint Res       Date:  2014-03-26       Impact factor: 5.853

8.  Effects of Steroids and Curcumin on Prevention of Laryngeal Stenosis Secondary to Trauma.

Authors:  Kamyar Iravani; Zahra Babaie; Mohammad-Javad Ashraf; Nader Tanideh
Journal:  Iran J Otorhinolaryngol       Date:  2016-07

9.  The matricellular functions of small leucine-rich proteoglycans (SLRPs).

Authors:  Rosetta Merline; Roland M Schaefer; Liliana Schaefer
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

10.  Fibroblast-like cells differentiated from adipose-derived mesenchymal stem cells for vocal fold wound healing.

Authors:  Rong Hu; Wei Ling; Wen Xu; Demin Han
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.